Clinical papers
Digistain® works biologically downstream using a proprietary method to measure markers at the protein level to deliver a robust and personalised risk score for cancer therapy guidance
Clinical Validation
Digistain is used to classify hormone-positive breast cancer patients by risk in a well characterised cohort of 801 patients from Nottingham City Hospital by evaluating a measure of Chromosomal instability (aneuploidy)
Performance of a novel spectroscopy-based tool for adjuvant therapy decision-making in hormone receptor-positive breast cancer: a validation study….
Published: 2024, Springer – Breast Cancer Research and Treatment
Validation of a novel and rapid reagent free assay to predict outcomes for adjuvant therapy decision making in hormone receptor-positive breast cancer…
Published: 2023 Journal of Clinical Oncology
Abstract P2-11-24: A Novel, Rapid and Economical Prognostic Tool For Adjuvant therapy Decisions in Hormone Positive Breast Cancer…
Published: 2023 American Association for Cancer Research
Biomarker Validation
Digistain evaluates existing and trusted biomarkers with independent prognostic value in breast cancer.
Role of chromosomal instability in cancer progression. Cancer cells often display chromosomal instability (CIN), a defect that involves loss or rearrangement…
Published: 2017 Society for Endocrinology, Endocrine-Related Cancer
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Complex focal chromosomal rearrangements…
Published: 2015 Molecular Oncology
Analytical Validation
Digistain maps concentration of aneuploidy in breast cancer
Mid-infrared imaging in breast cancer tissue: an objective measure of grading breast cancer biopsies. he majority of cancers are diagnosed using excised biopsy specimens…
Published: 2018 IOP Science
Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.
